AXIOS Lumen Apposing Metal Stent for Walled Off Necrosis Drainage IDE Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03525808|
Recruitment Status : Active, not recruiting
First Posted : May 16, 2018
Last Update Posted : June 25, 2020
|Condition or disease||Intervention/treatment||Phase|
|Walled Off Pancreatic Necrosis||Device: AXIOS||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Multicenter, Single-arm Study of Endoscopic Ultrasound-Guided Drainage of Walled-off Pancreatic Necrosis With Lumen-Apposing Metal Stents|
|Actual Study Start Date :||September 5, 2018|
|Actual Primary Completion Date :||March 13, 2020|
|Estimated Study Completion Date :||December 13, 2020|
Patients will receive the AXIOS stent for the treatment of walled-off pancreatic necrosis.
Patient will receive either transgastric or transduodenal endoscopic drainage for walled-off necrosis that are adherent to the gastric or bowel wall.
- Resolution of WON with Endoscopic Drainage [ Time Frame: Up to 60 Days ]Resolution of WON with endoscopic drainage defined as radiographic decrease of WON size to ≤ 3cm evaluated by CT scan or MRI
- AXIOS stent related or WON drainage procedure related serious adverse events [ Time Frame: Through study completion, average of 8 months ]AXIOS stent related or WON drainage procedure related serious adverse events
- Symptom Reduction [ Time Frame: Through study completion, average of 8 months ]Reduction of WON-related clinical symptoms. Note: WON-related symptoms as defined in Inclusion Criteria #4
- Technical Stent Placement Success [ Time Frame: Intraoperative (Stent placement) ]Technical AXIOS stent placement success, defined as placement in desired location using endoscopic/EUS techniques per standard of practice.
- Technical Stent Removal Success [ Time Frame: Intraoperative (Stent removal) ]Technical AXIOS stent removal success, defined as ability to remove the AXIOS stent using an endoscopic snare or forceps or graspers without AXIOS stent removal related serious adverse events.
- Drainage Procedural Time [ Time Frame: Intraoperative (Stent placement) ]Time elapsed between initial puncture of the WON with electrocautery to endoscope retrieval.
- Resolution of WON: Radiographic resolution evaluated by MRI or CT [ Time Frame: Through study completion, average of 8 months ]Resolution of WON with or without necrosectomy by 6 months post AXIOS stent removal.
- Time to WON Resolution [ Time Frame: Up to 60 Days ]
Time to WON resolution using same definition as for primary endpoint, namely:
- Resolution of WON with endoscopic drainage defined as radiographic decrease of WON size to ≤ 3cm evaluated by CT scan or MRI.
- WON Recurrence [ Time Frame: Through study completion, average of 8 months ]Recurrence of WON after initial resolution and up to 6 months post AXIOS stent removal.
- Stent Lumen Patency [ Time Frame: Intraoperative (Stent placement through stent removal) ]
Stent lumen patency, evaluated via imaging or direct visual inspection with endoscope, and defined as one or both of the following:
- Drainage through AXIOS stent visualized from the stomach or bowel, and/or
- Visual confirmation of AXIOS stent lumen patency
- Fluoroscopy [ Time Frame: Intraoperative (Stent placement through stent removal) ]Fluoroscopy (time) per endoscopic procedure.
- Incidence of New Organ Failure [ Time Frame: Up to 60 days ]Incidence of new organ failure from drainage procedure to WON resolution.
- Change in SF-12 Score [ Time Frame: At baseline, stent removal (up to 60 days) , and end of study visit (average of 8 months) ]Change in Quality of Life score (SF-12 questionnaire) from baseline to stent removal and end of study
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03525808
|United States, Colorado|
|University of Colorado, Denver|
|Aurora, Colorado, United States, 80045|
|United States, Georgia|
|Emory University Healthcare|
|Atlanta, Georgia, United States, 30322|
|United States, Indiana|
|Indiana University Health|
|Indianapolis, Indiana, United States, 46202|
|United States, Massachusetts|
|Brigham & Women's Hospital|
|Boston, Massachusetts, United States, 02115|
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|Principal Investigator:||Barham K Abu Dayyeh, MD||Mayo Clinic|